Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection.
Transient gene editing of the herpes simplex virus type 1 using mRNA-based CRISPR was shown for the first time to be effective against herpetic stromal keratitis in mice and blocked HSV-1 replication in human corneas, Chinese researchers reported in the January 11, 2021, online edition of NatureBiotechnology.
